Singapore plans to list etomidate in vapes as illegal drug
'Vaping, especially those that are laced with etomidate, is increasing. It is causing quite serious concern among agencies, including the Ministry of Home Affairs [MHA] and Ministry of Health [MOH],' he told reporters.
Recently, authorities randomly tested more than 100 vapes that were seized, and one-third were found to contain etomidate. Pods that contain vape juice mixed with etomidate are also known as K-pods.
Ong also noted that there had also been some deaths, including those arising from traffic accidents as well as unnatural ones, where etomidate was implicated, and investigations were ongoing.
Vapes, or e-vaporisers, are banned in Singapore. They are controlled and enforced under the Tobacco (Control of Advertisements and Sales) Act. Etomidate is a controlled substance under the Poisons Act.
Under these Acts, users of drug-laced pods may be fined, but that will change when etomidate is listed under the Misuse of Drugs Act (MDA).
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South China Morning Post
10 hours ago
- South China Morning Post
China-Singapore team's nanovaccine suppresses cancer recurrence and spread in animal tests
A joint China-Singapore research team is using nanoparticle technology to create a cancer vaccine that has produced promising results in animal tests – reducing the regrowth and spread of tumours up to seven times more effectively than existing treatments. The nanovaccine attacks not only regular cancerous cells but also cancer stem cells (CSCs), which can lie dormant within tumours during treatment, only awakening when conditions are more favourable to the disease. The bioinspired approach developed by the researchers, led by Yang Yanlian from the National Centre for Nanoscience and Technology and Chen Xiaoyuan from the National University of Singapore, has potential for personalised cancer vaccines. The researchers detailed their findings in a paper published last month by the peer-reviewed Nature Nanotechnology. Post-surgical recurrence and metastasis of cancers are mainly driven by CSCs, which are highly resistant to conventional therapies. Some studies have even suggested that traditional treatments like radiotherapy may inadvertently promote their spread. The body's normal stem cells work continuously, whether generating blood or helping to renew the gut's lining every three to five days. But their unique self-renewal and unlimited proliferation qualities are also harboured by CSCs within tumours.
South China Morning Post
13 hours ago
- South China Morning Post
China's plan to boost drug coverage by commercial insurers no ‘magic wand', analysts say
Beijing's plan to publish China's first list of innovative drugs eligible for coverage by commercial health insurance will draw keen interest from pharmaceutical companies, but is not a 'magic wand', as insurers lack sufficient incentives to provide the coverage, analysts said. The National Healthcare Security Administration, in charge of the state-run basic healthcare insurance scheme, said in a policy document on July 1 that it would publish the list this year, primarily including drugs that were not covered by state insurance but were highly innovative and provided clear improvements in medical outcomes. The list would be a 'major attempt to better meet the public's multi-level and diverse drugs demand', said Huang Xinyu, head of the administration's medical services management department, on July 11, as reported by Xinhua. Both domestic and multinational drug developers will likely be drawn to the initiative, but the same cannot be said of insurers, said Webster Guo, principal at L.E.K. Consulting's China healthcare practice. 'There's likely no harm for drug companies to apply [to have their products included],' he said. 'If you are lagging behind your competitors, the downside could be significant.' But the situation presented an 'impossible triangle' for insurers, who would struggle to devise products that would achieve national coverage while providing sufficient reimbursement levels at a price that people were willing to pay, he said, because the source of funding was 'not solved'. Commercial health-insurance payouts of 383.8 billion yuan (US$53.5 billion) in 2023 covered only 6.8 per cent of total direct healthcare costs, while state basic health insurance covered 49.7 per cent and patients paid for 43.5 per cent themselves, according to the Shanghai Insurance Association.
South China Morning Post
17 hours ago
- South China Morning Post
CUHK start-ups eye silver economy's need for ‘wearable robotics'
A couple of health and medical device start-ups that got their start at the Chinese University of Hong Kong are seeking to enter the growing markets for elderly care and rehabilitation by selling their 'wearable robotics' technologies. Established last year, RT HealthTech has developed several soft inflatable joint support products. It plans to start selling them in two months, targeting elderly people with weaker joints and those with minor injuries who want to keep exercising to maintain muscle strength. They feature a rechargeable battery-powered mobile air-pumping system that can generate adjustable levels of force, said co-founder Raymond Tong Kai-yu in an interview earlier this month. 'The devices can keep knee and elbow joints in position, while providing an extra pair of 'artificial muscles' to reduce joint impact during physical activities,' said Tong, a professor and founding chairman of the university's Department of Biomedical Engineering. 'We are addressing the needs of the fast-growing silver economy.' The proportion of Hong Kong people aged 65 and over was projected to rise to 36 per cent in 2046 from 22.4 per cent in 2023, according to government projections. RT HealthTech was seeking to sell 1,000 units in the first three months at around HK$1,200 (US$153) each, Tong said. It planned to appoint a separate distributor for mainland China.
